(Adnkronos) - “Parlando dell’obiettivo principale dei trattamenti terapeutici della leucemia linfoblastica acuta possiamo dire che oggi è la guarigione. È formidabile poter affermare questo anche nei pazienti adulti oggi arruolati nei protocolli di ricerca”. Così Alessandro Rambaldi, professore di Ematologia presso l’università degli studi di Milano, a margine dell’evento con il quale Amgen ha illustrato i risultati dello studio clinico di Fase III E1910 che dimostrano come l'introduzione dell’anticorpo monoclonale bispecifico blinatumomab nella prima linea di trattamento aumenti significativamente la sopravvivenza globale dei pazienti affetti da leucemia linfoblastica acuta (Lla) da linfociti B Ph- di nuova diagnosi.
Category
🗞
NewsTranscript
00:00For many years, our ability to evaluate the response to treatments was entrusted to the microscope.
00:13But a microscope has a sensitivity, the ability to identify the persistence of leucemic cells in the bone marrow of a patient not higher than 1%.
00:25So we could define in remission a patient who still had an important amount of disease.
00:33Molecular technologies today allow us to identify the persistence of a leucemic cell in 100,000, up to 1 million.
00:45This allows us to predict the persistence of the disease and, unfortunately, its ability to lead to the recidivism of the patient, perhaps after months or years.
00:58This is a very important phase in the therapy strategy because this is the phase in which we can intervene early with the aim of eradicating,
01:10that is, to make the last leucemic cell disappear.
01:14So this is the centrality of the evaluations of this minimal residual disease, which is so important in the history of the care of these patients.
01:26The goal today is healing, and it is formidable to be able to affirm this even in adult patients.
01:36Today we employ up to 65-year-old patients in research protocols, with the aim of bringing them to healing.
01:45Treatment strategies must take into account the great biological heterogeneity.
01:52Under the name of acute lymphoblastic leukemia, many different types of diseases are hidden.
01:59And so, starting from the initial characterization of the disease, the best therapeutic path can be defined,
02:09the choice of transplant or the choice of innovative therapies, such as those of which we can speak today enthusiastically.